A great product is not enough
Pacific Edge, one of the few homegrown medical technology companies the NZX can actually point to, has just shown investors what reimbursement risk looks like when it stops being theoretical. The Dunedin firm’s FY26 operating revenue fell 47.4% to $11.5 million from $21.8 million the prior year. Total revenue dropped 44.7% to $13.6 million, and net loss after tax widened to $35.8 million from $29.9 million.
The cause traces to a single decision. Novitas, the Medicare Administrative Contractor with jurisdiction over Pacific Edge’s US laboratory, withdrew reimbursement for its Cxbladder bladder cancer tests, with coverage formally ending in April 2025. Medicare had been underwriting roughly 56 to 60% of operating revenue. As CEO Dr Peter Meintjes put it to NBR in June 2026, “it was like sprinting a marathon”.
Clinical merit didn’t save it
This is the part that should unsettle anyone backing a medtech play. Cxbladder is not a fringe product. Its Triage test was included in the American Urological Association’s microhematuria guidelines in February 2025. Pacific Edge had spent more than a decade commercialising Otago University science in the US market. None of it prevented the withdrawal, and a judicial review of the Novitas decision was unsuccessful.
The coverage determination process is regional and administrative, not a national clinical judgement. A contractor based in Texas had the unilateral power to halve a NZ-listed company’s top line and trigger a 13-month revenue collapse, regardless of the science behind the product. For investors, that is the single most important sentence in this story.
Surviving the burn
To its credit, management did not sit still. Pacific Edge had initially forecast a revenue blow of up to 70%, so the actual 47.4% decline beats its own grim baseline. APAC test volumes grew 7.9% to 5,406 tests, and private payer gains in the US plugged part of the Medicare hole. Total expenses fell 9.5% to $49.3 million, and monthly cash burn was cut from $3.3 million to $2.4 million across the two halves of the year.
But survival came at a cost to existing shareholders. The company’s net assets eroded from $26.0 million to $10.7 million in a single year, and cash fell to $7.8 million from $22.6 million. Two capital raises totalling $36.1 million, including a $25.4 million placement at $0.17 a share, kept the lights on, funded predominantly by investors already on the register. Meintjes called that loyalty “a fantastic result.” It was also the only thing standing between the company and the wall.
The same regulator that giveth
The recovery hinges on the same Novitas process that nearly killed it. In mid-May 2026, the contractor published a draft Local Coverage Determination proposing Medicare coverage for urine-based biomarker testing in hematuria evaluation. Cxbladder Triage and Triage Plus were specifically indicated, while legacy and competing products were excluded for insufficient evidence, handing Pacific Edge a potential competitive moat covering roughly 20 million Americans aged 65 and over.
The maths have also improved. The new Triage Plus product carries a Medicare price of US$1,328 per test, a 75% premium over the legacy US$760. As Meintjes told RNZ in May 2026, that means “more revenue per test, more margin per test, higher margin percentage per test.” Chairman Simon Flood called the draft a “defining milestone”.
What this means for medtech investors
The risk has not gone away. The auditor flagged material uncertainty around the LCD outcome and the need for further funding, and Pacific Edge still has to rebuild physician relationships scorched by a 13-month coverage gap. Meintjes conceded some doctors will say “this whole experience has left a bad taste in our mouths”.
The broader lesson is structural, not company-specific. Any business that lets a single foreign government payer control the majority of its revenue is one administrative ruling away from a crisis, no matter how good the product or how strong the clinical evidence. Pacific Edge’s survival is a genuine testament to management discipline and investor nerve. But the final determination, expected before the end of 2026, is the next gate, and the company is once again at the mercy of a process it cannot control.
Sources
- Pacific Edge revenue drops (2026-06-30)
- Pacific Edge FY26 Audited Financial Results – Advancing Medicare Coverage Goals; Costs Contained (2026-05-25)
- Pacific Edge confident of return to profitability (2026-05-25)
- Pacific Edge net loss widens to 35.8 million dollars as Dunedin cancer test maker pins return to profit on draft Medicare coverage (2026-05-25)
- Pacific Edge seeks up to $24 million from investors at 17 cents a share as Cxbladder revenue halves and the Medicare fight grinds on (2026-05-11)
- Pacific Edge’s (ASX:PEB) Medicare LCD for Cxbladder has landed, and the commercial maths have been rewritten (2026-05-25)